tiprankstipranks
Advertisement
Advertisement

OCUL Stock Latest News

3 Best Stocks With 140%+ Upside to Buy in September, According to Analysts
Market News3 Best Stocks With 140%+ Upside to Buy in September, According to Analysts
8d ago
GMAB
OCUL
Axpaxli’s Differentiated Long-Acting Profile and Multibillion-Dollar Potential Support Buy Rating and Unchanged $27 Price Target
PremiumRatings
Axpaxli’s Differentiated Long-Acting Profile and Multibillion-Dollar Potential Support Buy Rating and Unchanged $27 Price Target
19d ago
OCUL
Ocular Therapeutix Maintained at Buy as Axpaxli’s Superior Durability Supports Unchanged $18 Price Target
PremiumRatings
Ocular Therapeutix Maintained at Buy as Axpaxli’s Superior Durability Supports Unchanged $18 Price Target
23d ago
OCUL
Clear Street sees less competition for Ocular after EyePoint miss
PremiumThe Fly
Clear Street sees less competition for Ocular after EyePoint miss
23d ago
EYPT
OCUL
Ocular Therapeutix Earns Buy Rating as Axpaxli Differentiation and LUGANO TKI Data Bolster Confidence in Lead Asset
PremiumRatings
Ocular Therapeutix Earns Buy Rating as Axpaxli Differentiation and LUGANO TKI Data Bolster Confidence in Lead Asset
23d ago
OCUL
Ocular Therapeutix rises 10.4%
PremiumThe FlyOcular Therapeutix rises 10.4%
23d ago
OCUL
Ocular Therapeutix Faces Governance and Perception Risks from Insider Equity Compensation and Trading Practices
Premium
Company Announcements
Ocular Therapeutix Faces Governance and Perception Risks from Insider Equity Compensation and Trading Practices
1M ago
OCUL
Ocular Therapeutix Earns Buy Rating on Reduced Regulatory Risk and Strong Axpaxli NDA Visibility
Premium
Ratings
Ocular Therapeutix Earns Buy Rating on Reduced Regulatory Risk and Strong Axpaxli NDA Visibility
1M ago
OCUL
Ocular Therapeutix reports Q2 EPS (35c), consensus (39c)
PremiumThe Fly
Ocular Therapeutix reports Q2 EPS (35c), consensus (39c)
1M ago
OCUL
OCUL’s OTX-TKI Extension Study: Long-Term Safety Data Could Shape Wet AMD Market
PremiumCompany Announcements
OCUL’s OTX-TKI Extension Study: Long-Term Safety Data Could Shape Wet AMD Market
2M ago
OCUL
Blair adds American Express, Oracle to Conviction List in monthly update
PremiumThe Fly
Blair adds American Express, Oracle to Conviction List in monthly update
2M ago
P
CW
Ocular Therapeutix price target raised to $25 from $21 at H.C. Wainwright
PremiumThe Fly
Ocular Therapeutix price target raised to $25 from $21 at H.C. Wainwright
3M ago
OCUL
Ocular Therapeutix price target raised to $30 from $24 at Baird
PremiumThe FlyOcular Therapeutix price target raised to $30 from $24 at Baird
3M ago
OCUL
Ocular Therapeutix trading resumes
Premium
The Fly
Ocular Therapeutix trading resumes
3M ago
OCUL
Ocular Therapeutix Investor Day to highlight FDA alignment on Axpaxli NDA
Premium
The Fly
Ocular Therapeutix Investor Day to highlight FDA alignment on Axpaxli NDA
3M ago
OCUL
Ocular Therapeutix to resume trading at 9:15 am ET
PremiumThe Fly
Ocular Therapeutix to resume trading at 9:15 am ET
3M ago
OCUL
Ocular Therapeutix trading halted, news pending
PremiumThe Fly
Ocular Therapeutix trading halted, news pending
3M ago
OCUL
Ocular Therapeutix Expands Equity Plan and Confirms Leadership
PremiumCompany Announcements
Ocular Therapeutix Expands Equity Plan and Confirms Leadership
3M ago
8K
OCUL
Equity-Based Pay at Ocular Therapeutix Raises Insider Trading Perception and Governance Risks
PremiumCompany Announcements
Equity-Based Pay at Ocular Therapeutix Raises Insider Trading Perception and Governance Risks
4M ago
OCUL
Analyst Reiterates Buy Rating on OCUL, Keeps Axpaxli-Driven Price Target Unchanged at $18
PremiumRatingsAnalyst Reiterates Buy Rating on OCUL, Keeps Axpaxli-Driven Price Target Unchanged at $18
4M ago
OCUL
Axpaxli’s Strong Phase III Data and Favorable FDA Path Support Buy Rating and Unchanged $20 Price Target
Premium
Ratings
Axpaxli’s Strong Phase III Data and Favorable FDA Path Support Buy Rating and Unchanged $20 Price Target
4M ago
OCUL
Analyst Reiterates Buy on Axpaxli Ahead of NDA Filing and Key SOL-R/SOL-X Data Catalysts
Premium
Ratings
Analyst Reiterates Buy on Axpaxli Ahead of NDA Filing and Key SOL-R/SOL-X Data Catalysts
4M ago
OCUL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >